Log In
BCIQ
Print this Print this
 

AMG 420, BI 836909

  Manage Alerts
Collapse Summary General Information
Company Boehringer Ingelheim GmbH
DescriptionBispecific T cell engager (BiTE) that targets tumor necrosis factor (TNF) receptor superfamily member 17 (BCMA; TNFRSF17; CD269)
Molecular Target Tumor necrosis factor (TNF) receptor superfamily member 17 (BCMA) (TNFRSF17) (CD269)
Mechanism of Action 
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentPhase I
Standard IndicationMultiple myeloma (MM)
Indication DetailsTreat relapsed or refractory multiple myeloma (MM)
Regulatory Designation
PartnerAmgen Inc.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

0

0

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

09/01/2016

Undisclosed

Undisclosed

Undisclosed

Get a free BioCentury trial today